|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4,729 JPY | +1.42% |
|
+6.44% | +22.13% |
| Apr. 19 | Middle East Tensions Dent Asian Stock Markets | MT |
| Apr. 10 | Roche’s HER2-Low Metastatic Breast Cancer Diagnostic Test Secures CE Mark | MT |
(Reuters) - AstraZeneca said on Monday its cancer treatment, Enhertu, developed with Japan's Daiichi Sankyo delayed the progression of a form of advanced breast cancer in previously treated patients.
Enhertu met the main goal of a late-stage study testing the drug against a treatment pre-determined by physicians in people with HER2-positive metastatic breast cancer. The HER2 protein contributes to the growth and spread of breast cancer.
(Reporting by Pushkala Aripaka in Bengaluru; Editing by Vinay Dwivedi)
| 1st Jan change | Capi. | |
|---|---|---|
| +22.13% | 57.77B | |
| +27.92% | 672B | |
| +27.26% | 570B | |
| -4.59% | 360B | |
| +16.38% | 321B | |
| +9.39% | 300B | |
| +7.42% | 217B | |
| +5.40% | 199B | |
| -8.63% | 204B | |
| -8.58% | 149B |
DAIICHI SANKYO CO., LTD. 
